Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HS-10353 in Chinese Adults
NCT05195203Phase 1Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jan 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing HS-10353 with Placebo (2 arms). Primary endpoints: Adverse Events and Serious Adverse Events. Started Jan 2021; status: completed.
02
Drugs
HS-10353
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05195203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05195203.